Immunome 8-K: Leadership/Compensation Changes Reported Jan 31, 2024
Ticker: IMNM · Form: 8-K · Filed: Feb 1, 2024 · CIK: 1472012
| Field | Detail |
|---|---|
| Company | Immunome Inc. (IMNM) |
| Form Type | 8-K |
| Filed Date | Feb 1, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $425,000, $16 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: corporate-governance, executive-changes, compensation
TL;DR
**Immunome filed an 8-K about executive changes on Jan 31, keep an eye out for details.**
AI Summary
Immunome, Inc. filed an 8-K on February 1, 2024, reporting an event that occurred on January 31, 2024. This filing indicates a change related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.' While the specific details of the changes are not provided in this excerpt, this matters to investors because changes in leadership or executive compensation can signal shifts in company strategy, financial health, or future performance, potentially impacting the stock price of IMNM.
Why It Matters
Changes in executive leadership or compensation can significantly influence a company's direction and investor confidence, directly affecting Immunome's stock valuation.
Risk Assessment
Risk Level: medium — The filing indicates significant corporate governance changes, which can introduce uncertainty regarding future company performance and strategy.
Analyst Insight
A smart investor would await further details on the specific changes in leadership or compensation arrangements to assess their potential impact on Immunome's strategic direction and financial outlook before making any investment decisions.
Key Players & Entities
- Immunome, Inc. (company) — the registrant filing the 8-K
- January 31, 2024 (date) — date of the earliest event reported
- February 1, 2024 (date) — date the 8-K was filed
- IMNM (company) — trading symbol for Immunome, Inc.
- The Nasdaq Capital Market (company) — exchange where Immunome's common stock is registered
FAQ
What was the specific date of the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 31, 2024.
What is the primary item information category for this 8-K filing?
The primary item information category for this 8-K filing is 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers'.
What is the trading symbol for Immunome, Inc. as stated in the filing?
The trading symbol for Immunome, Inc. is IMNM.
On which exchange is Immunome, Inc.'s Common Stock registered?
Immunome, Inc.'s Common Stock, with a $0.0001 par value per share, is registered on The Nasdaq Capital Market.
What is the business address of Immunome, Inc. as listed in the filing?
The business address of Immunome, Inc. is 665 Stockton Drive, Suite 300, Exton, Pennsylvania, 19342.
Filing Stats: 538 words · 2 min read · ~2 pages · Grade level 12.1 · Accepted 2024-01-31 21:18:44
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IMNM The Nasdaq
- $425,000 — ased Mr. Rosett's annual base salary to $425,000 and granted Mr. Rosett an option to pur
- $16 — tion has an exercise price per share of $16.57, which was the closing price of the
Filing Documents
- tm244837d1_8k.htm (8-K) — 24KB
- 0001104659-24-009012.txt ( ) — 193KB
- immu-20240131.xsd (EX-101.SCH) — 3KB
- immu-20240131_lab.xml (EX-101.LAB) — 33KB
- immu-20240131_pre.xml (EX-101.PRE) — 22KB
- tm244837d1_8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. IMMUNOME, INC. Date : January 31, 2024 By: /s/ Clay Siegall Clay Siegall, Ph.D. President and Chief Executive Officer